Business Context and Reporting Period
Company: Harvard Bioscience, Inc. (HBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: March 8, 2022
Reporting Period: The filing announces financial results for the three and twelve months ended December 31, 2021.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. The filing text itself does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific numerical metrics.
Material Changes
The filing text does not contain specific data regarding material changes versus prior periods. It only confirms the issuance of results for the periods ended December 31, 2021.
Guidance, Outlook, and Management Commentary
- Conference Call: Management scheduled a conference call for March 8, 2022, at 8:00 AM ET to discuss the results.
- Legal Disclaimer: The information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for Q4 and FY 2021.
- Verify the details of the conference call held on March 8, 2022, for management commentary on operational trends.
- Confirm whether the press release contains updated forward-looking guidance or outlook statements.
- Check for any specific risk factors or contingencies disclosed in the full press release text not summarized in this 8-K.